Ind-Swift Laboratories' Q1 FY 2026-27 Quarterly Results

Result Summary

• Ind-Swift Laboratories Ltd reported a 15.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 19.0%.
• Its expenses for the quarter were up by 7.4% QoQ and 6.0% YoY.
• The net profit increased 63.3% QoQ and increased 181.4% YoY.
• The earnings per share (EPS) of Ind-Swift Laboratories Ltd stood at 2.84 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Ind-Swift Laboratories Ltd is a pharmaceutical company engaged in the manufacturing and marketing of a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company operates in the highly competitive pharmaceutical industry, which is characterized by rapid innovation and stringent regulatory requirements. As of the latest update, there have been no major developments available for Ind-Swift Laboratories Ltd beyond October 2023. The company continues to focus on expanding its product offerings and strengthening its market presence in both domestic and international markets.

Revenue

In the first quarter of the fiscal year 2027 (Q1FY27), Ind-Swift Laboratories Ltd reported a total income of ₹199.11 crores. This represents a significant increase of 15.8% compared to the previous quarter (Q4FY26), where the total income was ₹172.01 crores. Furthermore, compared to the same quarter in the previous year (Q1FY26), the company experienced a year-over-year growth of 19.0%, as the total income in Q1FY26 was ₹167.32 crores. These figures reflect a positive trend in the company's revenue generation capabilities over both the quarterly and annual periods.

Profitability

The profitability of Ind-Swift Laboratories Ltd showed notable improvement in Q1FY27. The company achieved a profit before tax (PBT) of ₹32.56 crores, which is a substantial increase of 172.2% from the previous quarter's PBT of ₹11.96 crores. Year-over-year, the PBT grew by 214.6%, up from ₹10.35 crores in Q1FY26. After accounting for taxes, the profit after tax (PAT) for Q1FY27 was ₹24.68 crores, showcasing a 63.3% increase from Q4FY26's PAT of ₹15.11 crores and a remarkable 181.4% rise compared to Q1FY26's PAT of ₹8.77 crores. Earnings per share (EPS) also mirrored this upward trajectory, increasing to ₹2.84 in Q1FY27, up 61.4% from the previous quarter and 142.7% year-over-year.

Operating Metrics

The total expenses for Ind-Swift Laboratories Ltd in Q1FY27 amounted to ₹166.31 crores, marking an increase of 7.4% from Q4FY26's expenses of ₹154.91 crores. On a year-over-year basis, expenses rose by 6.0%, compared to ₹156.96 crores in Q1FY26. Despite the increase in expenses, the company managed to significantly enhance its profitability, as evidenced by the sharp increase in both PBT and PAT. The tax expense for Q1FY27 was ₹7.99 crores, a notable change from a tax credit of ₹-3.15 crores in Q4FY26, and an increase from the tax expense of ₹1.71 crores in Q1FY26. This change in tax expenses indicates a shift in the company's tax liabilities over the reported periods.